Carmignac Gestion Biogen Inc. Transaction History

Carmignac Gestion

  • $5.71 Billion
  • Q2 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024
BUY
$222.59 - $267.94 $11.6 Million - $14 Million
52,295 Added 16.92%
361,395 $93.5 Million
Q3 2023

Nov 13, 2023
SELL
$253.3 - $285.89 $253,300 - $285,890
-1,000 Reduced 0.32%
309,100 $79.4 Million
Q1 2023

May 12, 2023
BUY
$256.56 - $292.34 $79.6 Million - $90.7 Million
310,100 New
310,100 $86.2 Million

Others Institutions Holding BIIB

# of Institutions
1,018
Shares Held
128M
Call Options Held
1.22M
Put Options Held
1.4M
View Full List

About BIOGEN INC.

BIIB Quotes by TradingView
  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $25B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Carmignac Gestion Portfolio

Follow Carmignac Gestion and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Carmignac Gestion, based on Form 13F filings with the SEC.

News

Stay updated on Carmignac Gestion with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email